查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1600013

癌症藥物市場：按給藥途徑、治療類型、類型和最終用戶分類 - 全球預測 2025-2030

Cancer Drugs Market by Route of Administration (Intravenous, Oral, Topical), Type of Therapy (Chemotherapy, Combination Therapy, Hormonal Therapy), Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症治療市值為1445億美元，預計到2024年將達到1577.6億美元，複合年成長率為9.57%，到2030年將達到2740.5億美元。

癌症藥物市場包括旨在治療各種形式癌症的各種治療解決方案。這個市場包括化療、免疫療法、標靶治療、荷爾蒙療法和其他創新療法。全球癌症發病率上升、醫療技術進步以及對早期檢測和治療方案認知的提高支持了對抗癌藥物的需求。這些藥物有多種最終用戶應用，包括醫院、診所和專門的癌症治療中心。市場成長的主要影響因素包括製藥公司研發投入的增加、精準醫療的重大進展以及新型抗癌藥物核准率的提高。人口老化的迅速增加和生活方式的改變進一步推動了對有效癌症治療的需求。潛在的治療機會在於個人化醫療的日益採用和生物相似藥的日益接受，它們提供了具有成本效益的治療選擇。公司可以透過專注於開發針對個別患者情況的生物相似藥和精準醫療來利用這些機會。然而，新興市場也面臨著高昂的藥物開發成本、嚴格的監管要求以及癌症病理生理學的複雜性等限制，這些限制阻礙了創新和市場進入。此外，與癌症治療相關的副作用對廣泛接受提出了挑戰。創新和研究將專注於增強藥物輸送系統、探索聯合治療以及利用人工智慧進行早期診斷和個人化治療規劃，從而為公司提供成長之路，同時改善患者的治療效果。癌症藥物市場競爭激烈，技術進步頻繁，策略聯盟頻繁。成功的公司是那些保持營運靈活性、利用新興技術並有效駕馭監管環境、及時將有效的新治療方法推向市場的公司。

主要市場統計
基準年[2023] 1,445億美元
預測年份 [2024] 1577.6億美元
預測年份 [2030] 2740.5億美元
複合年成長率（%） 9.57%

市場動態：揭示快速發展的癌症藥物市場的關鍵市場洞察

供需的動態交互作用正在改變癌症藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 癌症疾病增加和認知提高
    • 政府和醫療機構對癌症治療的支持措施
  • 市場限制因素
    • 抗癌藥物研發成本高及產品召回問題
  • 市場機會
    • 基因組和分子研究的進展導致個人化癌症治療
    • 加大學名藥研發投入
  • 市場挑戰
    • 與癌症藥物相關的嚴格監管要求

波特五力：駕馭癌症藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對癌症藥物市場的影響

外部宏觀環境因素在塑造癌症治療市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解癌症治療藥物市場的競爭狀況

對癌症治療藥物市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣癌症治療市場供應商的績效評估

FPNV定位矩陣是評估癌症治療市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪癌症治療市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，癌症藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 癌症疾病的數量和認知的增加
      • 政府和衛生機構支持癌症治療的努力
    • 抑制因素
      • 與癌症藥物相關的高研發成本和產品召回問題
    • 機會
      • 基因組和分子研究的進步帶來個人化癌症治療
      • 加大學名藥研發投入
    • 任務
      • 與癌症藥物相關的嚴格監管要求
  • 市場區隔分析
    • 治療類型：由於長期緩解且副作用較少，免疫療法越來越受到青睞
    • 最終用戶：個人化健康計畫在居家照護中越來越受歡迎
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章癌症藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 話題

第7章依治療類型分類的癌症治療藥物市場

  • 化療
  • 聯合治療
  • 荷爾蒙療法
  • 免疫療法
  • 放射治療
  • 標靶治療

第8章癌症治療市場：按類型

  • 膀胱癌
  • 乳癌
  • 子宮頸癌
  • 大腸直腸癌
  • 食道癌
  • 腎癌
  • 肝癌
  • 肺癌
  • 攝護腺癌
  • 胃癌

第9章癌症藥物市場：依最終用戶分類

  • 診所
  • 居家護理
  • 醫院

第10章美洲抗癌藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太癌症藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的癌症藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Lantern Pharmaceuticals 和 OHSU 合作利用人工智慧開發先進的癌症治療方法
    • 工業以 24 億美元收購 Decifera Pharmaceuticals 以加強腫瘤產品組合
    • Zydus Lifesciences 推出新藥 Ivira，擴大印度癌症治療選擇
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Bayer AG
  • Biogen MA Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Eli Lilly and Company
  • F. Hofmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Incyte Corporation
  • Ipsen Pharma
  • Johnson & Johnson Services, Inc.
  • Mallinckrodt PLC
  • Merck KGaA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi Group
  • Sumitomo Pharma Co., Ltd.
  • Sun Pharmaceuticals Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-431B7BFFBF7B

The Cancer Drugs Market was valued at USD 144.50 billion in 2023, expected to reach USD 157.76 billion in 2024, and is projected to grow at a CAGR of 9.57%, to USD 274.05 billion by 2030.

The cancer drugs market encompasses a diverse range of therapeutic solutions aimed at treating various forms of cancer. This market includes chemotherapy, immunotherapy, targeted therapy, hormone therapy, and other innovative treatments. The necessity of cancer drugs is underscored by the rising prevalence of cancer globally, advancing medical technology, and increasing awareness about early detection and treatment options. These drugs find application across multiple end-users such as hospitals, clinics, and specialized cancer treatment centers. Key influencing factors for market growth include heightened investment in R&D by pharmaceutical companies, significant advancements in precision medicine, and the increasing approval rates of new cancer drugs. The surge in geriatric population and lifestyle changes further expedite the demand for effective cancer treatments. Potential opportunities lie in the rising adoption of personalized medicine and the growing acceptance of biosimilars, which provide cost-effective treatment alternatives. Companies can leverage these opportunities by intensifying their focus on developing biosimilars and precision medicine tailored to individual patient profiles. However, the market also faces limitations such as high costs of drug development, rigorous regulatory requirements, and the complex nature of cancer pathophysiology, which can hamper innovation and market entry. Additionally, side effects associated with cancer treatments pose challenges to widespread acceptance. Innovation and research could pivot towards enhancing drug delivery systems, exploring combination therapies, and leveraging AI for early diagnosis and personalized treatment plans, thereby offering businesses growth avenues while improving patient outcomes. The cancer drugs market is increasingly competitive, characterized by frequent technological advancements and strategic collaborations. Companies that will succeed are those that maintain agility in their operations, capitalize on emerging technologies, and navigate regulatory landscapes effectively to bring new, effective treatments to market in a timely manner.

KEY MARKET STATISTICS
Base Year [2023] USD 144.50 billion
Estimated Year [2024] USD 157.76 billion
Forecast Year [2030] USD 274.05 billion
CAGR (%) 9.57%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Drugs Market

The Cancer Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing number and awareness of cancer diseases
    • Governments and health organizations' supportive initiatives for cancer treatment
  • Market Restraints
    • High R&D cost and product recall issues associated with cancer drug
  • Market Opportunities
    • Advancements in genomic and molecular research leading to personalized cancer treatments
    • Increasing investment in generic medicine development
  • Market Challenges
    • Stringent regulatory requirements associated with cancer drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Drugs Market

A detailed market share analysis in the Cancer Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Drugs Market

A strategic analysis of the Cancer Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., AstraZeneca PLC, Bayer AG, Biogen MA Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, Eli Lilly and Company, F. Hofmann-La Roche Ltd., Gilead Sciences, Inc., GlaxoSmithKline PLC, Incyte Corporation, Ipsen Pharma, Johnson & Johnson Services, Inc., Mallinckrodt PLC, Merck KGaA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Group, Sumitomo Pharma Co., Ltd., Sun Pharmaceuticals Limited, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Cancer Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Route of Administration, market is studied across Intravenous, Oral, and Topical.
  • Based on Type of Therapy, market is studied across Chemotherapy, Combination Therapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, and Targeted Therapy.
  • Based on Type, market is studied across Bladder Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Esophagus Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Prostate Cancer, and Stomach Cancer.
  • Based on End-User, market is studied across Clinics, Homecare, and Hospitals.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing number and awareness of cancer diseases
      • 5.1.1.2. Governments and health organizations' supportive initiatives for cancer treatment
    • 5.1.2. Restraints
      • 5.1.2.1. High R&D cost and product recall issues associated with cancer drug
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genomic and molecular research leading to personalized cancer treatments
      • 5.1.3.2. Increasing investment in generic medicine development
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements associated with cancer drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type of therapy : Increasing preference for immunotherapy due to its long-term remission and reduced side effects
    • 5.2.2. End-user : Rising preference for personalized medicine plans in homecare
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Drugs Market, by Route of Administration

  • 6.1. Introduction
  • 6.2. Intravenous
  • 6.3. Oral
  • 6.4. Topical

7. Cancer Drugs Market, by Type of Therapy

  • 7.1. Introduction
  • 7.2. Chemotherapy
  • 7.3. Combination Therapy
  • 7.4. Hormonal Therapy
  • 7.5. Immunotherapy
  • 7.6. Radiation Therapy
  • 7.7. Targeted Therapy

8. Cancer Drugs Market, by Type

  • 8.1. Introduction
  • 8.2. Bladder Cancer
  • 8.3. Breast Cancer
  • 8.4. Cervical Cancer
  • 8.5. Colorectal Cancer
  • 8.6. Esophagus Cancer
  • 8.7. Kidney Cancer
  • 8.8. Liver Cancer
  • 8.9. Lung Cancer
  • 8.10. Prostate Cancer
  • 8.11. Stomach Cancer

9. Cancer Drugs Market, by End-User

  • 9.1. Introduction
  • 9.2. Clinics
  • 9.3. Homecare
  • 9.4. Hospitals

10. Americas Cancer Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Lantern Pharmaceuticals and OHSU Join Forces to Develop Advanced AI-Driven Cancer Treatments
    • 13.3.2. Ono Pharmaceutical Acquires Deciphera Pharmaceuticals in USD 2.4 Billion Deal to Bolster Oncology Portfolio
    • 13.3.3. Zydus Lifesciences Expands Cancer Treatment Options in India with Launch of New Drug Ibyra
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Amgen Inc.
  • 3. Astellas Pharma Inc.
  • 4. AstraZeneca PLC
  • 5. Bayer AG
  • 6. Biogen MA Inc.
  • 7. Boehringer Ingelheim GmbH
  • 8. Bristol-Myers Squibb Company
  • 9. Cipla Limited
  • 10. Eli Lilly and Company
  • 11. F. Hofmann-La Roche Ltd.
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Incyte Corporation
  • 15. Ipsen Pharma
  • 16. Johnson & Johnson Services, Inc.
  • 17. Mallinckrodt PLC
  • 18. Merck KGaA
  • 19. Novartis AG
  • 20. Pfizer, Inc.
  • 21. Regeneron Pharmaceuticals, Inc.
  • 22. Sanofi Group
  • 23. Sumitomo Pharma Co., Ltd.
  • 24. Sun Pharmaceuticals Limited
  • 25. Takeda Pharmaceutical Company Limited
  • 26. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CANCER DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DRUGS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DRUGS MARKET SIZE, BY HORMONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DRUGS MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DRUGS MARKET SIZE, BY BLADDER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DRUGS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DRUGS MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DRUGS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DRUGS MARKET SIZE, BY ESOPHAGUS CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DRUGS MARKET SIZE, BY KIDNEY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DRUGS MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DRUGS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DRUGS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DRUGS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DRUGS MARKET SIZE, BY HOMECARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES CANCER DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 69. CHINA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 73. INDIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 74. INDIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. INDONESIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 78. INDONESIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. INDONESIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. JAPAN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. JAPAN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. JAPAN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. MALAYSIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 86. MALAYSIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. MALAYSIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 89. PHILIPPINES CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 90. PHILIPPINES CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. PHILIPPINES CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. SINGAPORE CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 94. SINGAPORE CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SINGAPORE CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH KOREA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. TAIWAN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. TAIWAN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. TAIWAN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. THAILAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 106. THAILAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. THAILAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. VIETNAM CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 110. VIETNAM CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. VIETNAM CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. DENMARK CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 119. DENMARK CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. DENMARK CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 122. EGYPT CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 123. EGYPT CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. EGYPT CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. FINLAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. FINLAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. FINLAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. FRANCE CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 131. FRANCE CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. FRANCE CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. GERMANY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 135. GERMANY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. GERMANY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. ISRAEL CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 139. ISRAEL CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. ISRAEL CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. ITALY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. ITALY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. ITALY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 146. NETHERLANDS CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 147. NETHERLANDS CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. NETHERLANDS CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. NIGERIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 151. NIGERIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. NIGERIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. NORWAY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 155. NORWAY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. NORWAY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. POLAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 159. POLAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. POLAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 162. QATAR CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. QATAR CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. QATAR CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. RUSSIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 167. RUSSIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. RUSSIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 171. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SAUDI ARABIA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH AFRICA CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 178. SPAIN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 179. SPAIN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. SPAIN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. SWEDEN CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. SWEDEN CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. SWEDEN CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 186. SWITZERLAND CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 187. SWITZERLAND CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 188. SWITZERLAND CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. TURKEY CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 191. TURKEY CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 192. TURKEY CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED ARAB EMIRATES CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
  • TABLE 199. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. UNITED KINGDOM CANCER DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 202. CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2023